Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
about
The many faces of neuroendocrine differentiation in prostate cancer progressionTargeting the adaptive molecular landscape of castration-resistant prostate cancerUsing circulating tumor cells to inform on prostate cancer biology and clinical utilityThe link between androgen receptor splice variants and castration-resistant prostate cancer.Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.Aggressive variants of castration-resistant prostate cancerThe molecular basis for ethnic variation and histological subtype differences in prostate cancer.New strategies in prostate cancer: translating genomics into the clinicCirculating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostateMolecular pathways and targets in prostate cancerTissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.De novo large cell neuroendocrine carcinoma of the prostate, case report and literature reviewProstate cancer and neuroendocrine differentiation: more neuronal, less endocrine?Hyperpolarized 13C MR for molecular imaging of prostate cancer.Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification.Establishing prostate cancer patient derived xenografts: lessons learned from older studiesSubclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine CarcinomaTranslational and clinical implications of the genetic landscape of prostate cancer.GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Androgen receptor splice variants in the era of enzalutamide and abiraterone.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.FOXA1 inhibits prostate cancer neuroendocrine differentiation.Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Mapping Complex Traits in a Diversity Outbred F1 Mouse Population Identifies Germline Modifiers of Metastasis in Human Prostate Cancer.Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.Neuroendocrine differentiation of prostate cancer.What's New in SCLC? A Review.
P2860
Q26992049-67EF128B-7C40-428A-AA89-1BC9752244F1Q27022821-3F308584-F1E9-4943-81B1-74B55AFE835BQ28083261-33B3F783-162C-4A5C-B3A9-7EE86E7A7DB5Q30618562-DA220A0D-2092-4C7D-BC1E-737A8D6F0008Q33622362-4BD0FF7C-2A5A-436E-B2B5-F122D5E7284CQ33693256-8DFEA064-1096-465F-B597-BF06336D361CQ33835864-1AEDFFF3-87EF-4BBA-A704-BE43CE2CD754Q34007943-69704945-39EA-40E0-A201-8C1227B4CCBDQ34108738-1DFC91AE-E4A8-4312-8831-106E47C26E8CQ34216236-480205D2-9E3D-4F1E-A808-284035B10C4BQ34365187-00BBC021-0ACE-4B00-8950-9D2EAA1D0EFEQ34365632-505862E9-056D-4756-892A-3B44599503B1Q34383988-4EB27E72-350B-4EFB-BF00-AA7E3E0148A6Q34978736-AB1A5E18-466E-4027-BC6F-A5131B2CE9F2Q35141115-B7335DF4-3421-415A-B529-54C2C9CC4947Q35146434-8E8CACDA-BA68-4258-ABD0-8867E5F333B2Q35551492-40201C06-B64A-46AF-BF5C-E454C7039B16Q35556598-1B0D562D-3D05-4D8F-AA69-8692AF2617C7Q36030759-FE8A9EF3-ABCA-4D59-8ED0-DBF4701C687CQ36688923-1B9360F4-A8A6-4CF7-B731-6756354D806EQ36805567-DB505B40-37B4-4C28-AB86-28C5FD510CBFQ37270512-BD33876A-C6B3-44B4-BD4E-29F151CEE99CQ37564369-4C74F7AB-2972-4A4B-94F9-BA9FA0B77025Q37709535-9B45BBB1-71B8-4C1A-8422-338590CBE3C6Q38192816-D03C5EDE-3997-4A0F-8D55-867DF506CCCBQ38206682-18D710B1-D4A1-470A-990D-A48616DA3ED3Q38209356-5317AEFF-A049-4A3C-80F8-1911D432C9D5Q38232413-C1271A38-4396-4EC4-A3FE-175FFBC8F10DQ38374417-1005AB9F-FD8E-4ABA-A66B-2F0E0E6EE9B4Q38750084-D7493D8B-28B1-463C-8C31-128933C27190Q38768101-A4B5A688-45E7-44BC-AB34-ED613D9808A3Q38893882-222D5D0D-6149-4EBD-BC77-5CBEA2D7D18EQ38905865-4E0D1E09-3F43-4818-B35F-FE2733B08D37Q38923020-F7D921C5-646A-452F-80A3-15080F2B10C7Q38937417-31C58F47-EDE6-46A7-8C7D-4F2549DDEE4EQ39016544-B9EB7F42-581A-4044-9D34-C1B662C92EBFQ39132258-5DF2AAB7-F968-4095-BD70-DB2FDA23C8C6Q39155556-07C69555-1B49-4898-8FAC-E5C987B1FA62Q39179651-E7D833B4-5DDB-44B4-A32E-AE7D7208D425Q40049841-833302CD-CC0A-42AA-BDF5-E67DAAD8AA8D
P2860
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
description
im Dezember 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 19 November 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2012
@uk
name
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@en
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@nl
type
label
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@en
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@nl
prefLabel
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@en
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
@nl
P2093
P356
P1476
Challenges in recognizing treatment-related neuroendocrine prostate cancer
@en
P2093
David M Nanus
Himisha Beltran
Juan Miguel Mosquera
Kyung Park
Matthew I Milowsky
Scott T Tagawa
Theresa MacDonald
P304
P356
10.1200/JCO.2011.41.5166
P407
P50
P577
2012-11-19T00:00:00Z